

Last Updated on: 24 February 2012

### **General Grant Information**

| Country   | Myanmar                            | yanmar   |               |                         |                |  |  |  |  |  |
|---|------------------------------------|--|---------------|-------------------------|----------------|--|--|--|--|--|
| Grant Number  | MYN-S10-G07-M                      | Component Malaria R  |               | Round                   | SSF            |  |  |  |  |  |
| Grant Title   | Malaria control through<br>Myanmar | laria control through rapid and massive scale up of prevention, early diagnosis and effective treatment in anmar |               |                         |                |  |  |  |  |  |
| Principal Recipient                                     | United Nations Office fo           | ited Nations Office for Project Services, Myanmar  |               |                         |                |  |  |  |  |  |
| Total Lifetime Budget                                   | \$ 47,119,272                      | Current<br>Commitment  | \$ 19,262,714 | Phase 2 Grant<br>Amount | Not Applicable |  |  |  |  |  |
| Grant Start Date  | 01 Jan 2011                        | Current<br>Commitment End<br>Date  | 31 Dec 2012   | Phase 2 End Date        | Not Applicable |  |  |  |  |  |
| Disbursed Amount  | \$ 17,014,111                      | % of Grant Amount  | 88%           | Latest Rating           | A1             |  |  |  |  |  |
| Time Elapse (at the end of the latest reporting period) | 9 months                           | % of Grant Duration  | 38%           | Proposal Lifetime       | 130 months     |  |  |  |  |  |

#### MYN-S10-G07-M

Last Updated on: 24 February 2012

#### **New GPR Report - Table of Contents**

(For ExternalVersion)

#### 1. Program Description and Contextual Information

- 1.1. Grant Summary Web
- 1.2. Country Latest Statistics
- 1.3. Comments on Key Discrepancies between Approved Proposal and Grant Agreement
- 1.4. Conditions Precedent

#### 2. Key Grant Performance Information

- 2.1. Program Goals, Impact and Outcome Indicators
- 2.2. Programmatic Performance
  - 2.2.1. Reporting Periods
  - 2.2.2. Program Objectives, Service Delivery Areas and Indicators
  - 2.2.3. Cumulative Progress To Date
- 2.3. Financial Performance
  - 2.3.1. Grant Financial Key Performance Indicators (KPIs)
  - 2.3.2. Program Budget
  - 2.3.3. Program Expenditures
  - 2.3.4. Graph Cumulative Program Budget, Expenditures and Disbursement to Date
- 2.4. Progress Update and Disbursement Information
- 2.5. Contextual Information

#### MYN-S10-G07-M

Last Updated on: 24 February 2012

### 1. Program Description and Contextual Information

#### 1.1. Grant Summary - Web

Malaria is one of the top three priority public health problems in Myanmar. The program supported by this grant aims to reduce Malaria morbidity and mortality by at least 50 percent by 2015 and to contribute towards socio-economic development and the Millennium Development Goals. The proposal was based on the National Strategic Plan (NSP) for Malaria prevention and control, following international best practices. The proposal is implemented based on a Dual Track Financing scheme; it builds on and takes into account lessons learned from existing national Malaria Control Program and from the Malaria projects of other partners. The program targets the population at risk of Malaria in the areas of programme implementation and high risks groups including migrant workers and communities in remote poorly served populations. The objective of this grant is to prevent Malaria using long lasting insecticidal nets (LLINs) and insecticide-treated mosquito nets (ITNs) in high and moderate-risk villages in 180 townships and strengthen technical and administrative management capacity for Malaria control at all levels. The activities focus on the provision of prompt, effective anti-Malaria treatment and implementation of Behaviour Change Communication (BCC) to maximize appropriate use of ITNs and LLINs and early access to diagnosis and effective treatment.

| 1.2. Country Latest Statistics                            |            |           |  |
|---|------------|-----------|--|
| Background and Health Spending                            | Estimate   | Year      | Source   |
| Total population (in 1000s)                               | 47,963     | 2010      | United Nations. World Population Prospects:<br>.The 2010 Revision  |
| Pop age 0-4 (in 1000s)                                    | 3,956      | 2010      | United Nations. World Population Prospects:<br>.The 2010 Revision  |
| Pop age 15-49 (in 1000s)                                  | 27,314     | 2010      | United Nations. World Population Prospects:<br>.The 2010 Revision  |
| Physicians (number)                                       | 23,709     | 2000-2010 | WHO. World Health Statistics 2011  |
| Nursing and midwifery personnel (number)                  | 41,424     | 2000-2010 | WHO. World Health Statistics 2011  |
| Infant mortality rate (per 1,000 live births)             | 50         | 2010      | UNICEF. Child mortality database (http://www.childinfo.org/mortality_imrcountrydat a.php) accessed on 01 December 2011             |
| Under-5 mortality rate (per 1,000 live births)            | 66         | 2010      | UNICEF. Child mortality database (http://www.childinfo.org/mortality_ufmrcountryd ata.php) accessed on 01 December 2011            |
| Income level  | Low income | 2011      | World Bank. World Development Indicators database  |
| Total health expenditure per capita (USD)                 | 12         | 2008      | WHO. World Health Statistics 2011  |
| ODA commitments in health sector (Current US\$ millions)) | 64         | 2009      | .OECD  |
| ODA commitments in all sectors (Current US\$ millions)    | 364        | 2009      | .OECD  |
| Human development index                                   | low        | 2011      | UNDP. Human development index (http://hdr.undp.org/en/media/HDR_2011_EN_T able1.pdf) accessed on 01 December 2011                  |
| Malaria   | Estimate   | Year      | Source   |
| Reported malaria cases (suspected)                        | 1,095,474  | 2009      | .WHO. World malaria report 2010  |
| Reported malaria cases (probable and confirmed)           | 591,492    | 2009      | .WHO. World malaria report 2010  |
| Reported malaria deaths                                   | 972        | 2009      | .WHO. World malaria report 2010  |
| Estimated malaria deaths                                  | 9,097      | 2006      | .WHO. World malaria report 2008  |
| DALYs ('000), Malaria                                     | 303        | 2004      | WHO.<br>(http://www.who.int/healthinfo/global_burden_disease/gbddeathdalycountryestimates2004.xls)<br>accessed on 01 December 2011 |
| Nets distributed (ITNs and LLINs)                         | 39,000     | 2011      | Global Fund-supported programs, end 2011 results   |

#### MYN-S10-G07-M

Last Updated on: 24 February 2012

1.3. Comments on Key Discrepancies between Approved Proposal and Grant

|     | onditions Precedent   |         |         |               |                   |          |
|-----|---|---------|---------|---------------|-------------------|----------|
| CP# | Condition Precedent   | CP Type | Tied To | Terminal Date | Is currently met? | Comments |
|     | 1. Conditions Precedent to First Disbursement (Terminal Date as stated in block 7A of the Face Sheet) The first disbursement of Grant funds by the Global Fund to the Principal Recipient is subject to the satisfaction of each of the following conditions:  a) the delivery by the Principal Recipient to the Global Fund of the Principal Recipient's operating procedures for managing the flow of Grant funds from the time of Global Fund disbursement through to the funds arriving in the Myanmar Country Office of the Principal Recipient, including the operating procedures for the exchange and management of Grant funds in local currency; and b) the delivery by the Principal Recipient to the Global Fund of an Internal Audit Plan, in form and substance satisfactory to the Global Fund, outlining the audit coverage at both Principal Recipient and Sub-recipient levels.   |         |         | 01.Jan.11     | Yes               |          |
|     | 2. Conditions Precedent to Disbursement to Sub-recipients The disbursement of Grant funds by the Global Fund to the Principal Recipient for activities implemented by Sub-recipients or the disbursement of Grant funds by the Principal Recipient to any Sub-recipient is subject to the satisfaction of each of the following conditions:  a) the delivery by the Principal Recipient to the Global Fund of the Principal Recipient's operating procedures for disbursements of Grant funds to the Sub-recipients; b) the delivery by the Principal Recipient to the Global Fund of a plan, in form and substance satisfactory to the Global Fund, for the oversight of Sub-recipients; c) the delivery by the Principal Recipient to the Global Fund of evidence, in form and substance satisfactory to the Global Fund, that the Principal Recipient has assessed the capacity of each Sub-recipient and confirmed that each Sub-recipient either meets the minimum Global Fund requirements in relation to financial management or has developed a capacity building plan to address any significant weaknesses identified; and d) the delivery by the Principal Recipient to the Global Fund of a plan, in form and substance satisfactory to the Global Fund, for the audit of the expenditures of Sub Recipients under the Program. |         |         |               | Yes               |          |

### MYN-S10-G07-M

| CP# | Condition Precedent  | CP Type | Tied To | Terminal Date | Is currently met? | Comments |
|-----|--|---------|---------|---------------|-------------------|----------|
| 3   | 3. Conditions Precedent to Disbursement for Procurement of Health Products (as defined in Article 18 of the Standard Terms and Conditions)  The disbursement by the Global Fund to the Principal Recipient of Grant funds to finance the procurement of Health Products is subject to the satisfaction of each of the following conditions:  a) the delivery by the Principal Recipient to the Global Fund of a plan for the procurement, use and supply management of Health Products for the Program as described in subsection (b) of Article 18 of the Standard Terms and Conditions of this Agreement (the "PSM Plan"); b) the written approval by the Global Fund of the PSM Plan; and c) the delivery by the Principal Recipient to the Global Fund, of evidence, in form and substance satisfactory to the Global Fund, that the Principal Recipient has recruited qualified staff members to manage the Procurement and Supply Management of Health Products for the Program. |         |         |               | In Progress       |          |
| 4   | 4. Conditions Precedent to Disbursement or Use of Grant funds for upgrading of the storage and distribution system of the Health Products (Terminal Date as stated in block 7B of the Face Sheet) The disbursement by the Global Fund or use by the Principal Recipient of Grant funds to finance the upgrading of the storage and distribution system of the Health Products is subject to the satisfaction of each of the following conditions:  a) the delivery by the Principal Recipient to the Global Fund, in form and substance satisfactory to the Global Fund, of an assessment report of the storage and distribution system of the Health Products; and b) the delivery by the Principal Recipient to the Global Fund, in form and substance satisfactory to the Global Fund, of a costed work plan for such upgrading, which shall include timeframes and deliverables for priority improvements.   |         |         | 15.Feb.11     | In Progress       |          |
| 5   | C. SPECIAL TERMS AND CONDITIONS FOR THIS AGREEMENT  1. The parties to this Agreement acknowledge that as of the date of this Agreement, the Global Fund has received the commitment of the Host Government to the following: (a) to issue renewable annual multi-entry visas for the Principal Recipient and the Local Fund Agent personnel in advance of their start dates of employment as notified by either the Principal Recipient or the Local Fund Agent, and (b) to allow the Principal Recipient, the Local Fund Agent, and the Global Fund representatives ad-hoc access to project implementation sites.  |         |         |               | Yes               |          |
| 6   | 2. The Parties to this Agreement acknowledge and agree that expenditure of Grant funds or implementation of the Program activities shall not take place in locations where staff members or individuals contracted and acting on behalf of the Principal Recipient, Sub recipients, the Local Fund Agent or the Global Fund are denied access. The Principal Recipient acknowledges and agrees that in the event that the Principal Recipient, Sub-recipients, Local Fund Agent or the Global Fund are denied access to project sites, the Global Fund may discontinue the funding for activities occurring in such project site or resort to remedies of suspension and termination under this Agreement.   |         |         |               | Yes               |          |

### MYN-S10-G07-M

| CP# | Condition Precedent  | CP Type | Tied To | Terminal Date | Is currently met? | Comments |
|-----|--|---------|---------|---------------|-------------------|----------|
| 7   | 3. In the event that an additional Sub-recipient is selected during the Commitment Period, the Parties to this Agreement acknowledge and agree that prior to the disbursement of Grant funds by the Principal Recipient to such Subrecipient, the Principal Recipient shall furnish to the Global Fund, in form and substance satisfactory to the Global Fund, the following: i. evidence demonstrating that the Principal Recipient has conducted a comprehensive assessment of the Sub-recipient; ii. evidence demonstrating that the Principal Recipient has signed an agreement with the Sub-recipient, which, without limitation, shall include a budget, workplan, implementation and financial and programmatic reporting responsibilities of the Sub-recipient; iii. details identifying the financial institution or institutions into which Grant funds will be disbursed for the benefit of the Sub-recipient; and iv. documentation demonstrating that the Subrecipient has received training on monitoring and evaluation responsibilities sufficient to meet its requirements under the Program. |         |         |               | Not started       |          |
| 8   | 4. Notwithstanding Section C.3 above, the Global Fund reserves the right to request the assessment by the Local Fund Agent of any additional Sub-recipient selected in accordance with this Agreement.   |         |         |               | Not started       |          |
| 9   | 5. The Principal Recipient and the Global Fund agree that, without the prior written approval of the Global Fund, the Principal Recipient shall not advance Grant funds to any implementing entity, except for the United Nations entities and the International Union against Tuberculosis and Lung Disease. With exception of the funding provided by the Principal Recipient to United Nations entities and the International Union against Tuberculosis and Lung Disease, the Principal Recipient shall provide funding to implementing entities only on a reimbursable basis by adhering to a zero cash balance policy, which limits funding to either a) reimbursing actual expenditures made in accordance with budgets and work plans which have been verified by the Principal Recipient or b) by the Principal Recipient making direct payments to vendors for goods and services procured to support the activities of such implementing entities.  |         |         |               | Yes               |          |
| 10  | 6. The advance of Grant funds to implementing entities for activities at the township level is subject to the satisfaction of each of the following conditions:  a) the delivery by the Principal Recipient to the Global Fund of a plan, in form and substance satisfactory to the Global Fund, for the management of the fund flow process at the township level (the "Fund Flow Mechanism"); and b) the written approval by the Global Fund of the Fund Flow Mechanism.   |         |         |               | Yes               |          |

#### MYN-S10-G07-M

| CP# | Condition Precedent   | CP Type | Tied To | Terminal Date | Is currently met? | Comments |
|-----|---|---------|---------|---------------|-------------------|----------|
| 11  | 7. The Global Fund reserves the right to unilaterally revoke the operation of the Fund Flow Mechanism and request the Principal Recipient to submit to the Global Fund for approval an adjusted Fund Flow Mechanism plan to implement the activities covered under this system using a zero cash balance policy as defined under Section C.5. In this event, the Principal Recipient shall be entitled to submit a request to access the supplementary funds budgeted for the financial management and implementation of the zero cash balance policy related to the activities previously covered under the Fund Flow Mechanism. For the avoidance of doubt, parties acknowledge that supplementary funds are currently budgeted in the amount of US\$102,000 and may not be utilized for any other purpose, without written approval of the Global Fund.  |         |         |               | In Progress       |          |
| 12  | 8. The Principal Recipient and the Global Fund acknowledge and agree that the financing of activities implemented by the Sub-recipients shall be subject to the foregoing conditions:  a. Grant funds shall only be used to provide support for the following: i) health care and service provision, ii) patient support costs, iii) the supply management function, iv) provision of essential equipment, v) monitoring, supervision and coordination of Program activities, vi) training, vii) technical and management support to enable decentralised levels of civilian administrations to manage and monitor service delivery, and viii) domestic travel and accommodation costs incurred in the course of implementation of the Program. b. Domestic travel and accommodation costs incurred in the course of the implementation of the Program by Sub-recipients other than UN agencies and the International Union against Tuberculosis and Lung Disease shall not exceed the costs authorized by the rules established by the United Nations Development Programme for Myanmar. The Principal Recipient shall endeavor to harmonize the rates and rules with those being applied by the 3 Diseases Fund. c. International travel and accommodation expenses incurred in the course of the implementation of the Program shall be subject to Global Fund approval. d. Program activities in support of the government agencies at national, divisional/state, district, township health authority or local civilian administrative level or below must be included in the work plans and budgets of United Nations agencies and such actions, including fund disbursement and commodity provision, shall be monitored by the Principal Recipient at least on a quarterly basis. e. Support to government-implemented components of the national programs shall not include staff salaries and allowances, recruitment fees, international fellowships, recurrent costs or expenses for rehabilitation of Ministry of Health facilities without prior written approval of |         |         |               | In Progress       |          |

#### MYN-S10-G07-M

| CP# | Condition Precedent  | CP Type | Tied To | Terminal Date | Is currently met? | Comments |
|-----|--|---------|---------|---------------|-------------------|----------|
| 13  | 9. The Principal Recipient acknowledges and agrees that percentage-based overheads or cost recovery fees of Sub-recipients shall not exceed the amounts established in the budget approved by the Global Fund, unless the Global Fund has expressly authorized in writing the payment of higher amounts. Sub-recipients in receipt of such payments, other than United Nations entities, shall submit their organization's annual Audited Financial Statements upon request of the Global Fund.  |         |         |               | Yes               |          |
| 14  | 10. The parties to this Agreement acknowledge and agree that cost recovery charges levied by the Principal Recipient under this Agreement shall be made in accordance with rates mutually agreed by the Principal Recipient and the Global Fund.   |         |         |               | In Progress       |          |
| 15  | 11. During the term of this Agreement the Principal Recipient shall maintain a minimum level of staffing consisting, without limitation, of the following professionals of experience and qualifications competitive at international level: a Program Coordinator, a Finance Officer, a Monitoring and Evaluation Officer and a Procurement Officer. In the event that consultants are contracted to cover gaps caused by delays in recruitment, such consultants must have equivalent qualifications and experience.   |         |         |               | In Progress       |          |
| 16  | 12. The Principal Recipient shall ensure that vehicles or other fixed assets procured or leased by the Principal Recipient or any implementing entity, using Grant funds may be made available to the Host Government or national entities only on a loan basis. The Principal Recipient shall use its best efforts to ensure that vehicles and other fixed assets which have been made available to the Host Government or national entities, by the Principal Recipient or any other implementing entity, including Sub-recipients, on a loan basis are used for Program activities only. The Principal Recipient and implementing entities, including Sub-recipients, shall maintain log books for all vehicles and fixed assets. The Principal Recipient and implementing entities shall ensure that the location of such vehicles and/or fixed assets are known at all times and are available for inspection b |         |         |               | In Progress       |          |
| 17  | 13. The Parties to this Agreement acknowledge and agree that the procurement of supplies and equipment using Grant funds, including supplies and equipment to support the activities of implementing entities, shall be conducted exclusively by the Principal Recipient. The procurement of Health Products will be governed by the Standard Terms and Conditions of this Agreement and Section C.14 of this Agreement.   |         |         |               | In Progress       |          |
| 18  | 14. The Principal Recipient acknowledges and agrees that the procurement of Health Products with the use of Grant funds shall be done through a suitably qualified Procurement Agent (as assessed by the Local Fund Agent and approved by the Global Fund in writing) until the Global Fund has agreed in writing, upon relevant assessment by the Local Fund Agent, that such procurement can be properly managed by the Principal Recipient.   |         |         |               | Yes               |          |

### MYN-S10-G07-M

| CP# | Condition Precedent  | CP Type | Tied To | Terminal Date | Is currently met? | Comments |
|-----|--|---------|---------|---------------|-------------------|----------|
| 19  | 15. In accordance with Articles 18(b)(2), 18(c) and 18(g) of the Standard Terms and Conditions of this Agreement, the parties agree that the procurement of Medicines will strictly follow the list contained in the PSM Plan, which may include Medicines whose registration has been waived by the National Drug Regulatory Authority of the Union of Myanmar.   |         |         |               | Yes               |          |
| 20  | 16. No later than 30 June 2011, the Principal Recipient shall deliver to the Global Fund evidence, in form and substance satisfactory to the Global Fund, that the Principal Recipient has established a functional system for storage, distribution, recording and reporting and utilization of information to manage the program, recording and reporting on patient and inventory related information (Management Information System), including a system for validating analyzing and utilizing the reported information in the management of the programs. The Principal Recipient shall also deliver to the Global Fund, Standard Operating Procedures for storage, distribution of health products, and recording and reporting and utilization of information to manage the program. The procedures shall also take into account the requirements of the Global Fund, Quality Assurance Policy on Finished Pharmaceutical Products and the reporting requirements with respect to the Price and Quality Reporting (PQR). |         |         | 30.Jun.11     | Not started       |          |
| 21  | 17. The Global Fund reserves the right to conduct periodic reviews of the Procurement and Supply Management function of the Principal Recipient.   |         |         |               | In Progress       |          |
| 22  | 18. The Principal Recipient shall notify the Global Fund in advance of any proposed changes to the implementation arrangements described in this Agreement. Such proposed change in the implementation arrangements shall be subject to the prior written approval of the Global Fund.   |         |         |               | In Progress       |          |
| 23  | 19. The Principal Recipient shall ensure that the Oversight Plan for Sub-recipients (as described in Section B.2.b above) and the Internal Audit Plan (as described in Section B.1.b above) is implemented as scheduled and shall report any findings arising to the Global Fund on a quarterly basis including measures to address issues identified.   |         |         |               | In Progress       |          |
| 24  | 20. No later than 1 February 2011, the Principal Recipient shall deliver to the Global Fund a Conflict of Interest Policy signed by all personnel working for the Principal Recipient on the Program.  |         |         |               | In Progress       |          |
| 25  | 21. The Principal Recipient agrees that Grant funds cannot be used to finance WHO positions for the calendar year 2012 unless such support has been approved by the Global Fund by 30 June 2011.   |         |         |               | Yes               |          |
| 26  | 22. The Principal Recipient shall use its best efforts to co-ordinate the development of a national monitoring and evaluation plan for Malaria (the "National M&E Plan") and to submit a copy to the Global Fund. Prior to submission of the National M&E Plan to the Global Fund, the Principal Recipient shall, upon request, provide progress updates to the Global Fund.   |         |         |               | In Progress       |          |

### MYN-S10-G07-M

| CP# | Condition Precedent   | CP Type | Tied To | Terminal Date | Is currently met? | Comments |
|-----|---|---------|---------|---------------|-------------------|----------|
| 27  | 23. The Principal Recipient shall ensure that the United Nations operational rate of exchange applies to currency conversions from United States Dollars into Myanmar Kyats during the term of this Agreement in accordance with the procedures referred to in Section B.1.a above. Notwithstanding above, the parties acknowledge and agree that the International Union against Tuberculosis and Lung Disease is entitled to employ other competitive currency conversion rates, provided that best efforts are used to employ the most beneficial rate available in accordance with their own approved procedures. |         |         |               | In Progress       |          |
| 28  | 24. For the purposes of this Agreement, implementing entities shall include the Principal Recipient, Sub-recipients, Sub-sub-recipients and any other entity or individual that receives Grant funds for implementation of Program activities.  |         |         |               | Yes               |          |
| 29  | 25. Notwithstanding what provided for in Article 3(c) of the Standard Terms and Conditions of this Agreement, any interest or other earnings generated by any Sub-Recipient which is an organization of the United Nations system shall be treated in accordance with the financial rules and regulations of such Sub-recipient.  |         |         |               | In Progress       |          |
| 30  | 26. The Global Fund and the Principal Recipient agree that the detailed program evaluations mentioned in Article 15 of the Standard Terms and Conditions of this Agreement are limited to those evaluations previously agreed in the detailed Monitoring and Evaluation Plan.   |         |         |               | Yes               |          |

### MYN-S10-G07-M

Last Updated on: 24 February 2012

### 2. Key Grant Performance Information

| Year 1                    | Year 2   | Year 3                      | Year 4                      | Year 5                      | Year                        | 6 Y           | ear 7      | Year 8                            | Year 9     | Year 10    |  |
|---------------------------|--|-----------------------------|-----------------------------|-----------------------------|-----------------------------|---------------|------------|-----------------------------------|------------|------------|--|
| 2011                      | 2011   | 2013                        | 2014                        | 2015                        | 201                         | 6             | 2017       | 2018                              | 2019       | 2020       |  |
| Goal 1                    |  | nalaria morb                |                             |                             |                             |               |            | 6 by 2015 (base                   | eline 2007 | data), and |  |
| mpact indicato            |  |                             |                             | at are due to               |                             |               |            | iii Goais.                        | Baseline   | s          |  |
| impaot indicato           |  | diagnosis)                  | an adamo in                 | at are ade to               | maiana (por                 |               | indiana    | Value                             | Bassiiiis  | Year       |  |
|                           |  |                             |                             |                             |                             |               |            | 9.47%                             |            | 2008       |  |
|                           | Year 1   | Year 2                      | Year 3                      | Year 4                      | Year 5                      | Year 6        | Year 7     | Year 8                            | Year 9     | Year 10    |  |
| Target                    | N:   | N:                          | N:                          | N:                          | N:                          | N:            | N:         | N:                                | N:         | N:         |  |
| •                         | D:   | D:                          | D:                          | D:                          | D:                          | D:            | D:         | D:                                | D:         | D:         |  |
| Pocult                    | P: 10%   | P: 9%                       | P: 7%                       | P: 6%<br>N:                 | P: 5%                       | P: %          | P: %       | P: %                              | P: %<br>N: | P: %       |  |
| Result                    | N:<br>D:   | N:<br>D:                    | N:<br>D:                    | N:<br>D:                    | N:<br>D:                    | N:<br>D:      | N:<br>D:   | N:<br>D:                          | D:         | N:<br>D:   |  |
|                           | P: %   | P: %                        | P: %                        | P: %                        | P: %                        | P: %          | P: %       | P: %                              | P: %       | P: %       |  |
| Data source of Results    |  |                             |                             |                             |                             |               |            |                                   |            |            |  |
| mpact indicato            | r  | number and                  | proportion of               | malaria (con                | firmed) admis               | ssions amo    | ng all     |                                   | Baseline   | S          |  |
| ·                         |  | hospital adm                |                             | `                           | ,                           |               |            | Value                             |            | Year       |  |
|                           |  |                             |                             |                             |                             |               |            | 6.42% 47,5                        | 14         | 2008       |  |
|                           | Year 1   | Year 2                      | Year 3                      | Year 4                      | Year 5                      | Year 6        | Year 7     | Year 8                            | Year 9     | Year 10    |  |
| Target                    | N: 50,000  | N: 45,000                   | N: 35,000                   | N: 30,000                   | N: 25,000                   | N:            | N:         | N:                                | N:         | N:         |  |
| raiget                    | D: 714,286<br>P: 7%  | D: 692,308<br>P: 7%         | D: 700,000<br>P: 5%         | D: 750,000<br>P: 4%         | D: 714,286<br>P: 4%         | D:<br>P: %    | D:<br>P: % | D:<br>P: %                        | D:<br>P: % | D:<br>P: % |  |
| Result                    | N:   | N:                          | N:                          | N:                          | N:                          | N:            | N:         | N:                                | N:         | N:         |  |
| rtooun                    | D:   | D:                          | D:                          | D:                          | D:                          | D:            | D:         | D:                                | D:         | D:         |  |
|                           | P: %   | P: %                        | P: %                        | P: %                        | P: %                        | P: %          | P: %       | P: %                              | P: %       | P: %       |  |
| Data source of<br>Results |  |                             |                             |                             |                             |               |            |                                   |            |            |  |
| mpact indicato            | r  |                             |                             | med) cases r                | eported by he               | ealth worke   | ers (in    | <u> </u>                          | Baseline   | S          |  |
|                           |  | facilities and              | outreach)                   |                             |                             | Value         |            | Year                              |            |            |  |
|                           |  |                             |                             |                             |                             |               |            | 399559                            |            | 2008       |  |
|                           | Year 1   | Year 2                      | Year 3                      | Year 4                      | Year 5                      | Year 6        | Year 7     | Year 8                            | Year 9     | Year 10    |  |
| Target                    | 828,647  | 939,876                     | 914,732                     | 890,631                     | 770,616                     |               |            |                                   |            |            |  |
| Result                    |  |                             |                             |                             |                             |               |            |                                   |            |            |  |
| Data source of Results    |  |                             |                             |                             |                             |               |            |                                   |            |            |  |
| mpact indicato            | r  |                             |                             | of people fo                |                             |               |            | Baselines                         |            |            |  |
|                           |  | diagnostic te               | sting among                 | all slides or r             | apid diagnos                | tic tests tak | en         | Value                             |            | Year       |  |
|                           |  |                             |                             |                             |                             |               |            | Slide positivity=<br>RDT=not avai |            | 2009       |  |
|                           | Year 1   | Year 2                      | Year 3                      | Year 4                      | Year 5                      | Year 6        | Year 7     | Year 8                            | Year 9     | Year 10    |  |
| Target                    | Slide<br>positivity=4<br>2%<br>RDTpositivi<br>ty:baseline<br>established | Slide<br>positivity=4<br>2% | Slide<br>positivity=4<br>2% | Slide<br>positivity=3<br>5% | Slide<br>positivity=3<br>0% |               |            |                                   |            |            |  |
| Result                    |  |                             |                             |                             |                             |               |            |                                   |            |            |  |
| Data source of            | +  |                             |                             |                             |                             |               |            |                                   | _          |            |  |
| -ala ocuree U             | 1  | 1                           |                             | 1                           | I .                         | 1             |            |                                   |            |            |  |

### MYN-S10-G07-M

| Outcome indicat           | or                      | % of house         | holds with at      | least one LL        | .IN/ITN            |                  |                  |                     | Baseline         | es               |
|---------------------------|-------------------------|--------------------|--------------------|---------------------|--------------------|------------------|------------------|---------------------|------------------|------------------|
|                           |                         |                    |                    |                     |                    |                  |                  | Value               |                  | Year             |
|                           |                         |                    |                    |                     |                    |                  |                  | 5.65%               |                  | 2008             |
|                           | Year 1                  | Year 2             | Year 3             | Year 4              | Year 5             | Year 6           | Year 7           | Year 8              | Year 9           | Year 10          |
| Target                    | N:<br>D:<br>P: 53%      | N:<br>D:<br>P: 94% | N:<br>D:<br>P: 98% | N:<br>D:<br>P: 100% | N:<br>D:<br>P: 98% | N:<br>D:<br>P: % | N:<br>D:<br>P: % | N:<br>D:<br>P: %    | N:<br>D:<br>P: % | N:<br>D:<br>P: % |
| Result                    | N:<br>D:<br>P: %        | N:<br>D:<br>P: %   | N:<br>D:<br>P: %   | N:<br>D:<br>P: %    | N:<br>D:<br>P: %   | N:<br>D:<br>P: % | N:<br>D:<br>P: % | N:<br>D:<br>P: %    | N:<br>D:<br>P: % | N:<br>D:<br>P: % |
| Data source of<br>Results |                         |                    |                    |                     |                    |                  |                  |                     |                  |                  |
| Outcome indicat           | or                      | % of popula        | ation at risk s    | sleeping unde       | s night            |                  | Baseline         | es                  |                  |                  |
|                           |                         |                    |                    |                     |                    |                  |                  | Value               |                  | Year             |
|                           |                         |                    |                    |                     |                    |                  |                  | not available Jun-1 |                  | Jun-10           |
|                           |                         | % of popula        | ation at risk s    | leeping unde        | r an LLIN/ITI      | N the previous   | s night          | Baseline            |                  | es               |
|                           |                         |                    |                    |                     |                    |                  |                  | Value               |                  | Year             |
|                           |                         |                    |                    |                     |                    |                  |                  | not availab         | le               | Jun-10           |
|                           | Year 1                  | Year 2             | Year 3             | Year 4              | Year 5             | Year 6           | Year 7           | Year 8              | Year 9           | Year 10          |
| Target                    | baseline<br>established |                    |                    |                     |                    |                  |                  |                     |                  |                  |
| Result                    |                         |                    |                    |                     |                    |                  |                  |                     |                  |                  |
| Data source of<br>Results |                         |                    |                    |                     |                    |                  |                  |                     |                  |                  |
| Outcome indicat           | or                      | proportion of      | of confirmed       | malaria case        | s treated in a     | accordance wi    | ith              |                     | Baseline         | es               |
|                           |                         |                    | laria treatme      | ent guidelines      | within 24 ho       | ours of onset of | of               | Value               |                  | Year             |
|                           |                         | symptoms           |                    |                     |                    |                  |                  | 25%                 |                  | 2008             |
|                           | Year 1                  | Year 2             | Year 3             | Year 4              | Year 5             | Year 6           | Year 7           | Year 8              | Year 9           | Year 10          |
| Target                    | N:<br>D:<br>P: 30%      | N:<br>D:<br>P: 50% | N:<br>D:<br>P: 60% | N:<br>D:<br>P: 60%  | N:<br>D:<br>P: 60% | N:<br>D:<br>P: % | N:<br>D:<br>P: % | N:<br>D:<br>P: %    | N:<br>D:<br>P: % | N:<br>D:<br>P: % |
| Result                    | N:<br>D:<br>P: %        | N:<br>D:<br>P: %   | N:<br>D:<br>P: %   | N:<br>D:<br>P: %    | N:<br>D:<br>P: %   | N:<br>D:<br>P: % | N:<br>D:<br>P: % | N:<br>D:<br>P: %    | N:<br>D:<br>P: % | N:<br>D:<br>P: % |
| Data source of<br>Results |                         |                    |                    |                     |                    |                  |                  |                     |                  |                  |

#### MYN-S10-G07-M

Last Updated on: 24 February 2012

#### 2.2. Programmatic Performance

| 2.2.1. Reporting Periods |     |                        |                        |                        |                        |                        |          |          |                        |  |
|--------------------------|-----|------------------------|------------------------|------------------------|------------------------|------------------------|----------|----------|------------------------|--|
| ,                        |     | Period 1               | Period 2               | Period 3               | Period 4               | Period 5               | Period 6 | Period 7 | Period 8               |  |
|                          | N/A | 01.Jan.11<br>31.Mar.11 | 01.Apr.11<br>30.Jun.11 | 01.Jul.11<br>30.Sep.11 | 01.Oct.11<br>31.Dec.11 | 01.Jan.12<br>31.Mar.12 | - 1      |          | 01.Oct.12<br>31.Dec.12 |  |

#### 2.2.2. Program Objectives, Service Delivery Areas and Indicators

Objective 1 - Prevent malaria using insecticide treated nets an dlong lasting insecticidal nets in high and moderate villages in 180 townships

Prevention: Insecticide-treated nets (ITNs)

Indicator 1.1 - Number of LLINs distributed free of charge to people at risk

|          | Base   | eline | Is Top 10        | Is Training      |
|----------|--------|-------|------------------|------------------|
|          | Value  | Year  | indicator? (Y/N) | indicator? (Y/N) |
| No Level | 282846 | 2008  | Top 10 Equ.      | N                |

|        | Period 1 | Period 2  | Period 3  | Period 4  | Period 5  | Period 6  | Period 7  | Period 8  |
|--------|----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| Target | 0        | 0         | 281,226   | 482,451   | 240,000   | 600,000   |           |           |
| Result |          |           | 383,923   |           |           |           |           |           |
|        | Period 9 | Period 10 | Period 11 | Period 12 | Period 13 | Period 14 | Period 15 | Period 16 |
| Target | 28,451   |           |           |           |           |           |           |           |
| Result |          |           |           |           |           |           |           |           |

#### Indicator 1.2 - Number of mosquito nets treated with insecticide

|          | Baseline |      | ls Top 10        | Is Training      |  |
|----------|----------|------|------------------|------------------|--|
|          | Value    | Year | indicator? (Y/N) | indicator? (Y/N) |  |
| No Level | 852762   | 2008 | Top 10 Equ.      | N                |  |

|        | Period 1  | Period 2  | Period 3  | Period 4  | Period 5  | Period 6  | Period 7  | Period 8  |
|--------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| Target | 0         | 0         | 403,151   | 742,665   | 913,469   | 1,819,937 | 1,826,937 | 1,826,937 |
| Result |           |           | 0         |           |           |           |           |           |
|        | Period 9  | Period 10 | Period 11 | Period 12 | Period 13 | Period 14 | Period 15 | Period 16 |
| Target | 1,024,204 |           |           |           |           |           |           |           |
| Result |           |           |           |           |           |           |           |           |

#### MYN-S10-G07-M

Last Updated on: 24 February 2012

| Objective 2 - Strenghten public and private sector diagnostic and treatment services and maximis access to and utilization of these |
|---|
| services by the public  |

**Treatment: Diagnosis** 

Indicator 2.1 - Number of blood slides taken and examined

|          | Baseline |      | ls Top 10        | Is Training      |  |
|----------|----------|------|------------------|------------------|--|
|          | Value    | Year | indicator? (Y/N) | indicator? (Y/N) |  |
| No Level | 499296   | 2008 | N                | N                |  |

| Period 1 | Period 2      | Period 3            | Period 4   | Period 5   | Period 6   | Period 7  | Period 8  |
|----------|---------------|---------------------|--|--|--|---|---|
| 0        | 112,500       | 292,500             | 450,000  | 100,000  | 225,000  | 375,000   | 500,000   |
|          | 80,310        | 97,472              |  |  |  |   |   |
| Period 9 | Period 10     | Period 11           | Period 12  | Period 13  | Period 14  | Period 15   | Period 16   |
| 100,000  |               |                     |  |  |  |   |   |
|          |               |                     |  |  |  |   |   |
|          | 0<br>Period 9 | 0 112,500<br>80,310 | 0 112,500 292,500<br>80,310 97,472<br>Period 9 Period 10 Period 11 | 0     112,500     292,500     450,000       80,310     97,472       Period 9     Period 10     Period 11     Period 12 | 0 112,500 292,500 450,000 100,000<br>80,310 97,472<br>Period 9 Period 10 Period 11 Period 12 Period 13 | 0 112,500 292,500 450,000 100,000 225,000<br>80,310 97,472 Period 9 Period 10 Period 11 Period 12 Period 13 Period 14 | 0 112,500 292,500 450,000 100,000 225,000 375,000 80,310 97,472  Period 9 Period 10 Period 11 Period 12 Period 13 Period 14 Period 15 |

#### Indicator 2.2 - Number of rapid diagnostic tests done and read

|          | Base   | eline | ls Top 10        | Is Training      |  |
|----------|--------|-------|------------------|------------------|--|
|          | Value  | Year  | indicator? (Y/N) | indicator? (Y/N) |  |
| No Level | 543941 | 2008  | N                | N                |  |

|        | Period 1 | Period 2  | Period 3  | Period 4  | Period 5  | Period 6  | Period 7  | Period 8  |
|--------|----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| Target | 40,450   | 266,750   | 523,050   | 773,500   | 199,150   | 442,600   | 726,410   | 965,200   |
| Result | 19,716   | 45,097    | 430,557   |           |           |           |           |           |
|        | Period 9 | Period 10 | Period 11 | Period 12 | Period 13 | Period 14 | Period 15 | Period 16 |
| Target | 197,710  |           |           |           |           |           |           |           |
| Result |          |           |           |           |           |           |           |           |

#### Indicator 2.3 - Percentage of assessed malaria microscopists who meet the minimum national competency level

|          | Base                 | eline   | Is Top 10        | Is Training indicator? (Y/N) |  |
|----------|----------------------|---------|------------------|------------------------------|--|
|          | Value                | Year    | indicator? (Y/N) |                              |  |
| No Level | not<br>availabl<br>e | Sept-10 | N                | N                            |  |

|        | Period 1 | Period 2 | Period 3 | Period 4 | Period 5 | Period 6 | Period 7 | Period 8 |
|--------|----------|----------|----------|----------|----------|----------|----------|----------|
| Target |          |          |          |          |          |          |          |          |
| Result |          |          |          |          |          |          |          |          |

#### Indicator 2.4 - number of people with confirmed malaria treated with recommended ACT (disagregated by age group and sex)

|          | Base   | eline | ls Top 10        | Is Training      |
|----------|--------|-------|------------------|------------------|
|          | Value  | Year  | indicator? (Y/N) | indicator? (Y/N) |
| No Level | 394529 | 2008  | Top 10 Equ.      | N                |

|        | Period 1 | Period 2  | Period 3  | Period 4  | Period 5  | Period 6  | Period 7  | Period 8  |
|--------|----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| Target | 10,750   | 144,000   | 361,715   | 554,929   | 133,865   | 299,537   | 497,209   | 661,074   |
| Result | 6,080    | 13,158    | 213,655   |           |           |           |           |           |
|        | Period 9 | Period 10 | Period 11 | Period 12 | Period 13 | Period 14 | Period 15 | Period 16 |
| Target | 133,020  |           |           |           |           |           |           |           |
| Result |          |           |           |           |           |           |           |           |

#### MYN-S10-G07-M

Result

| Indicator 2.5 - Number of people with malaria ( | probable and confirmed | ) treated with chloroquine | (disaggregated by age group and sex) |
|---|------------------------|----------------------------|--------------------------------------|
|   |                        |                            |                                      |

| Indicator 2                | .5 - Number of pe                     | ople with                | malaria          | (probable and co         | nfirm | ned) treated v       | vith chlo | oroquine (         | disaggregated by   | age group and s    | ex)                |
|----------------------------|---------------------------------------|--------------------------|------------------|--------------------------|-------|----------------------|-----------|--------------------|--------------------|--------------------|--------------------|
|                            |                                       | Base<br>Value            | eline<br>Year    | Is Top 10 indicator? (Y/ | ′N)   | Is Traini indicator? |           |                    |                    |                    |                    |
| No Level                   |                                       | 239,751                  | 200              | 8 Top 10 Equ             | l.    | N                    |           |                    |                    |                    |                    |
|                            | Period 1                              | Period 2                 |                  | Period 3                 | Dori  | od 4                 | Period    | 5                  | Period 6           | Period 7           | Period 8           |
| Tanat                      |                                       | i ellou z                |                  |                          | 1 611 |                      | i enou    |                    |                    |                    |                    |
| Target                     | 9,000                                 |                          | 98,000           | 238,481                  | _     | 362,962              |           | 81,148             | 178,869            | 304,590            | 401,738            |
| Result                     | 6,818                                 |                          | 10,233           | 131,145                  |       |                      |           |                    |                    |                    |                    |
|                            | Period 9                              | Period 1                 | 0                | Period 11                | Peri  | od 12                | Period    | 13                 | Period 14          | Period 15          | Period 16          |
| Target                     | 88,884                                |                          |                  |                          |       |                      |           |                    |                    |                    |                    |
| Result                     |                                       |                          |                  |                          |       |                      |           |                    |                    |                    |                    |
|                            | .6 - Percentage o uring the past 3 m  |                          | cilities w       | vith no reported s       | tock  | outs of natio        | nality re | commend            | ded antimalarial d | rugs lasting more  | than 1 week at     |
| <u> </u>                   |                                       | Base                     | eline            | Is Top 10                |       | Is Traini            | na        |                    |                    |                    |                    |
|                            |                                       | Value                    | Year             | indicator? (Y            | /N)   | indicator?           |           |                    |                    |                    |                    |
| No Level                   |                                       | not<br>availabl<br>e     | Jun-1            | 0 N                      |       | N                    |           |                    |                    |                    |                    |
|                            | Period 1                              | Period 2                 |                  | Period 3                 | Peri  | od 4                 | Period    | 5                  | Period 6           | Period 7           | Period 8           |
| Target                     | N:<br>D:<br>P: %                      |                          | N:<br>D:<br>P: % | N:<br>D:<br>P: 80%       |       | N:<br>D:<br>P: 80%   |           | N:<br>D:<br>P: 80% | N:<br>D:<br>P: 90% | N:<br>D:<br>P: 90% | N:<br>D:<br>P: 90% |
| Result                     | N:<br>D:<br>P: %                      |                          | N:<br>D:<br>P: % | N:<br>D:<br>P: 95%       |       | N:<br>D:<br>P: %     |           | N:<br>D:<br>P: %   | N:<br>D:<br>P: %   | N:<br>D:<br>P: %   | N:<br>D:<br>P: %   |
|                            | Period 9                              | Period 1                 | 0                | Period 11                | Peri  | od 12                | Period    | 13                 | Period 14          | Period 15          | Period 16          |
| Target                     | N:<br>D:<br>P: 90%                    |                          | N:<br>D:<br>P: % | N:<br>D:<br>P: %         |       | N:<br>D:<br>P: %     |           | N:<br>D:<br>P: %   | N:<br>D:<br>P: %   | N:<br>D:<br>P: %   | N:<br>D:<br>P: %   |
| Result                     | N:<br>D:<br>P: %                      |                          | N:<br>D:<br>P: % | N:<br>D:<br>P: %         |       | N:<br>D:<br>P: %     |           | N:<br>D:<br>P: %   | N:<br>D:<br>P: %   | N:<br>D:<br>P: %   | N:<br>D:<br>P: %   |
| Indicator 2<br>those surve | .7 - Percentage o<br>eyed (disaggrega | f healthca<br>ted by cat | re provid        | ders who provide         | anti- |                      | ment a    |                    |                    |                    |                    |
|                            |                                       | Base                     | eline            | Is Top 10                |       | Is Traini            | ng        |                    |                    |                    |                    |
|                            |                                       | Value                    | Year             | indicator? (Y            | /N)   | indicator?           | (Y/N)     |                    |                    |                    |                    |
| No Level                   |                                       | not<br>availabl<br>e     | June<br>201      |                          |       | N                    |           | ,                  |                    |                    |                    |
|                            | Period 1                              | Period 2                 |                  | Period 3                 | Peri  | od 4                 | Period    | 5                  | Period 6           | Period 7           | Period 8           |
|                            |                                       |                          |                  |                          |       |                      |           |                    |                    |                    |                    |

#### MYN-S10-G07-M

Last Updated on: 24 February 2012

#### Objective 4 - Strengthen community based malaria control activities

Supportive Environment: Coordination and partnership development (national, community, public-private)

Indicator 4.1 - Number of village health volunteers trained and supported for malaria prevention and control

|          | Base  | eline | ls Top 10        | Is Training      |
|----------|-------|-------|------------------|------------------|
|          | Value | Year  | indicator? (Y/N) | indicator? (Y/N) |
| No Level | 136   | 2008  | Top 10 Equ.      | N                |

|        | Period 1 | Period 2  | Period 3  | Period 4  | Period 5  | Period 6  | Period 7  | Period 8  |
|--------|----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| Target | 224      | 2,324     | 4,439     |           | 1,792     | 4,717     |           | 4,757     |
| Result | 0        | 1,736     | 4,105     |           |           |           |           |           |
|        | Period 9 | Period 10 | Period 11 | Period 12 | Period 13 | Period 14 | Period 15 | Period 16 |
| Target | 1,782    |           |           |           |           |           |           |           |
| Result |          |           |           |           |           |           |           |           |

#### MYN-S10-G07-M

Last Updated on: 24 February 2012

#### Objective 5 - Strengthen technical and administraative management capacity for malaria control at all levels

**HSS:** Human resources

Indicator 5.1 - Number of health staff trained/retrained

|          | Base      | eline | ls Top 10        | Is Training      |
|----------|-----------|-------|------------------|------------------|
|          | Value     | Year  | indicator? (Y/N) | indicator? (Y/N) |
| No Level | 8147 2008 |       | Top 10 Equ.      | N                |

|        | Period 1 | Period 2  | Period 3  | Period 4  | Period 5  | Period 6  | Period 7  | Period 8  |
|--------|----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| Target | 129      | 2,489     | 4,084     | 5,959     | 5,429     | 13,189    | 13,988    | 14,813    |
| Result | 45       | 1,283     | 1,944     |           |           |           |           |           |
|        | Period 9 | Period 10 | Period 11 | Period 12 | Period 13 | Period 14 | Period 15 | Period 16 |
| Target | 279      |           |           |           |           |           |           |           |
| Result |          |           |           |           |           |           |           |           |

#### MYN-S10-G07-M

Last Updated on: 24 February 2012

#### 2.2.3. Cumulative Progress To Date

Latest reporting due period : 3 (01.Jul.11 - 30.Sep.11)

| Objective 1  | Prevent malaria using insecticide treated nets an dlong lasting insecticidal nets in high and moderate villages in 180 townships |    |       |    |      |  |  |  |           |  |  |
|--|--|----|-------|----|------|--|--|--|-----------|--|--|
| SDA  | Prevention: Insecticide-treated nets (ITNs)  |    |       |    |      |  |  |  |           |  |  |
| Indicator 1.1 - Number of LLINs distributed free of charge to people at risk |  |    |       |    |      |  |  |  |           |  |  |
|  |  | Ta | arget | Re | sult |  |  |  | 10<br>90% |  |  |
| Period Value Period Value & & & & & & & & & & & & & & & & & & &              |  |    |       |    |      |  |  |  |           |  |  |
| No Level 3 281,226 3 383,923 120%  |  |    |       |    |      |  |  |  |           |  |  |

| Indicator 1.2 - Number of mosquito nets treated with insecticide |        |       |        |       |    |     |     |     |  |  |
|--|--------|-------|--------|-------|----|-----|-----|-----|--|--|
|  | Та     | rget  | Result |       |    |     |     | 90% |  |  |
|  | Period | Value | Period | Value | 0% | 30% | 60% | 00% |  |  |
| No Level 3 403,151 3 0 0%  |        |       |        |       |    |     |     |     |  |  |

#### MYN-S10-G07-M

|  | tnese services  | by the public  | tor diagrio  | stic and tre   | eatment se   | ervices        | and ma     | iximis ac   |  | io ui       |                              |
|--|---|--|--|--|--|----------------|------------|-------------|--|-------------|------------------------------|
| SDA  | Treatment: Diag   | •  |  |  |  |                |            |             |  |             |                              |
| ndicator 2.1 - N   | umber of blood slides   | s taken and examin   | ed   |  |  |                |            |             |  |             |                              |
|  |   | Та   | rget   | Re   | sult   |                |            |             | 90%  | _           |                              |
|  |   | Period   | Value  | Period   | Value  | 0%             | 30%        | 60%         | 90%  | 00%         |                              |
| No Level   |   | 3  | 292,500  | 3  | 97,472   |                |            |             |  |             | 33%                          |
| Indiantor 2.2 No   | umber of rapid diagn  | actic tecto deve en  |  |  |  |                |            |             |  |             |                              |
| nuicator 2.2 - N   | uniber of rapid diagni  |  |  | Do   | عاديد  |                |            |             | 9  |             |                              |
|  |   | Period   | rget<br>Value  | Period   | sult<br>Value  |                | 30%        | 60%         | 90%  | 100%        |                              |
| No Level   |   | 3  | 523,050  | 3  | 430,557  | 0%             | %          | %           |  | \$          | 82%                          |
|  |   | 0  | 020,000  | 0  | 400,007  |                |            |             |  |             | /-                           |
| ndicator 2.3 - Pe  | ercentage of assesse  | d malaria microsco   | pists who  | meet the n   | ninimum r  | ational        | compe      | tency le    |  |             |                              |
|  |   | Та   | rget   | Re   | sult   |                | (1)        | •           | 90%  | <u> </u>    |                              |
|  |   | Period   | Value  | Period   | Value  | 0%             | 30%        | 60%         |  |             |                              |
| No Level   |   | N/A  |  | N/A  | Not<br>Found   |                |            |             |  | Ca          | innot Calculate              |
| Indicator 2.4 - nı   | umber of people with  | confirmed malaria  | treated wi   | th recomm  |  | ⊐<br>T (disad  | gregate    | d by age    | grou   | p an        | d sex)                       |
|  |   |  | rget   | 1  | sult   |                |            |             | 90   |             | ,                            |
|  |   | Period   | Value  | Period   | Value  | 0%             | 30%        | 60%         | %  | 100%        |                              |
| No Level   |   | 3  | 361.715  | 3  | 213,655  | <b>%</b>       | - 8        | 8           |  | ~           | 59%                          |
|  | umber of people with  |  |  | ,  |  | loroqui        | ne (disa   | aggregat    | 9  |             | group and se                 |
|  | uniber of people with   | Та   | ırget  | Re   | sult   |                |            |             | 9  |             | group and se                 |
| No Level   | uniber of people with   | Ta<br>Period   | rget<br>Value  | Re<br>Period   | sult<br>Value  | loroquii<br>0% | ne (disa   | aggregat    | 9  | age         |                              |
| No Level   | umber of people with  | Та   | ırget  | Re   | sult   |                |            |             | 9  |             | group and se                 |
| Indicator 2.6 - Pe   | ercentage of health fa  | Period 3   | Value 238,481  | Re Period 3  | Value<br>131,145   | 0%             | 30%        | 60%         | 90%  | 100%        | 55%                          |
| Indicator 2.6 - Pe   |   | Period 3 cilities with no repost 3 months  | Value<br>238,481<br>orted stoc   | Re Period 3  | Value<br>131,145   | 0%             | 30%        | 60%         | arial o  | 100%        | 55%                          |
| Indicator 2.6 - Pe   | ercentage of health fa  | Period 3 cilities with no repost 3 months  | Value 238,481  | Re Period 3  | Value 131,145 ationality   | recomn         | 30%        | antimal     | 90%  | 100%        | 55%                          |
| Indicator 2.6 - Po<br>than 1 week at a   | ercentage of health fa  | Period 3  cilities with no repost 3 months  Ta  Period   | Value 238,481  orted stoc  arget  Value  N:  | Re Period 3 k outs of n Re Period  | value 131,145 ationality sult Value N:   | recomn         | 30%        | 60%         | 90%  | 100%        | 55%                          |
| Indicator 2.6 - Po<br>than 1 week at a   | ercentage of health fa  | Period 3 cilities with no repast 3 months  | Value 238,481 orted stoc rrget Value   | Re Period 3 k outs of n  | Value 131,145 ationality sult Value  | recomn         | 30%        | antimal     | 90%  | 100%        | 55%                          |
| Indicator 2.6 - Pethan 1 week at a  No Level   | ercentage of health fa<br>ny time during the pa<br>ercentage of healthca                          | Period 3  collities with no replies 3 months  Tai  Period  3  are providers who p  | value 238,481  orted stoc  riget  Value  N: D: P: 80 %  provide ant  | Re Period 3 k outs of n Re Period 3  | value 131,145 ationality sult Value N: D: P: 95 % reatment a   | 0%             | 30%        | antimal     | arial o  | 100%        | 55% s lasting more           |
| Indicator 2.6 - Pothan 1 week at a  No Level  Indicator 2.7 - Po   | ercentage of health fa<br>ny time during the pa   | Period 3 Idilities with no repost 3 months  Ta Period  3 Identify the providers who posaggregated by categorian and providers who posaggregated by the providers who providers who posaggregated by categorian | value 238,481  orted stoc  rget Value N: D: P: 80 %  rovide antegories of  | Re Period 3 k outs of n Re Period 3  | value 131,145 ationality sult Value N: D: P: 95 % reatment a )   | 0%             | 30%        | antimal     | arial c  | 100%        | 55% s lasting more           |
| Indicator 2.6 - Pothan 1 week at a  No Level  Indicator 2.7 - Po   | ercentage of health fa<br>ny time during the pa<br>ercentage of healthca                          | Period 3 Idilities with no repost 3 months  Ta Period  3 Identify the providers who posaggregated by categorian and providers who posaggregated by the providers who providers who posaggregated by categorian | value 238,481  orted stoc  riget  Value  N: D: P: 80 %  provide ant  | Re Period 3 k outs of n Re Period 3  | value 131,145 ationality sult Value N: D: P: 95 % reatment a) sult   | o%             | nended     | antimal 60% | arial c  | 100%        | 55% s lasting more           |
| Indicator 2.6 - Po<br>than 1 week at a<br>No Level<br>Indicator 2.7 - Po<br>guidelines amor                  | ercentage of health fa<br>ny time during the pa<br>ercentage of healthca                          | Period  3  acilities with no repost 3 months  Ta  Period  3  are providers who period by care providers who period by care period  Ta  Period  | Value 238,481  orted stoc  riget  Value  N: D: P: 80 %  rovide antegories of   | Re Period 3 k outs of n Re Period 3 i-malaria to f providers Re Period                               | value 131,145  ationality  sult  Value  N: D: P: 95 %  reatment a)  sult  Value  Not                                       | 0%             | 30%        | antimal     | arial o  | 100% I trea | 55% s lasting more           |
| Indicator 2.6 - Po<br>than 1 week at a<br>No Level<br>Indicator 2.7 - Po<br>guidelines amor                  | ercentage of health fa<br>ny time during the pa<br>ercentage of healthca                          | Period 3 cilities with no replet 3 months  Ta Period 3 re providers who psaggregated by cal  | Value 238,481  orted stoc  riget  Value  N: D: P: 80 %  rovide antegories of   | Re Period 3 k outs of n Re Period 3 i-malaria tr providers Re  | value 131,145  ationality sult Value N: D: P: 95 % reatment a) sult Value  | o%             | nended     | antimal 60% | arial c  | 100% I trea | 55% s lasting more 119%      |
| Indicator 2.6 - Pothan 1 week at a  No Level  Indicator 2.7 - Poguidelines amor                              | ercentage of health fa<br>ny time during the pa<br>ercentage of healthca<br>ng those surveyed (di | Period  3  acilities with no repost 3 months  Ta  Period  3  are providers who period by care providers who period by care period  Ta  Period  | Value 238,481  orted stoc  rget  Value  N: D: P: 80 %  rrovide antegories of arget  Value                                      | Re Period 3 k outs of n Re Period 3 i-malaria tif providers Re Period N/A                            | sult Value 131,145  ationality  sult Value N: D: P: 95 % reatment a) sult Value Not Found                                  | o%             | nended     | antimal 60% | arial c  | 100% I trea | 55% s lasting more 119%      |
| Indicator 2.6 - Pothan 1 week at a  No Level  Indicator 2.7 - Poguidelines amor                              | ercentage of health fa<br>ny time during the pa<br>ercentage of healthca<br>ng those surveyed (di | Period 3  Icilities with no repost 3 months  Ta Period 3  Irre providers who period Ta Period N/A  | Value 238,481  orted stoc  riget  Value  N: D: P: 80 %  rovide antegories of   | Re Period 3 k outs of n Re Period 3 i-malaria tr f providers Re Period N/A                           | sult  Value  131,145  ationality  sult  Value  N: D: P: 95 %  reatment a)  sult  Value  Not Found                          | o%             | nended     | antimal 60% | arial contains an alaria   | 100% Ca     | 55% slasting more 119% tment |
| Indicator 2.6 - Pothan 1 week at a  No Level  Indicator 2.7 - Poguidelines amore  No Level  Objective 4  SDA | ercentage of health fa<br>ny time during the pa<br>ercentage of healthca<br>ng those surveyed (di | Period 3  acilities with no reports 3 months  Tail Period 3  are providers who presaggregated by care providers who presegged by the  | Value 238,481  orted stoc  rget  Value  N: D: P: 80 %  rrovide antegories of arget  Value  Value                               | Re Period 3 k outs of n Re Period 3 i-malaria tr f providers Re Period N/A ol activities             | sult  Value  131,145  ationality  sult  Value  N:     D:     P: 95 %  reatment a)  sult  Value  Not     Found  do developr | recomm         | nended 30% | antimal 60% | arial contains a second | 100%        | 55% slasting more 119% tment |
| Indicator 2.6 - Pothan 1 week at a  No Level  Indicator 2.7 - Poguidelines amore  No Level  Objective 4  SDA | ercentage of health fainy time during the pair ercentage of healthcang those surveyed (di         | Period 3  acilities with no repust 3 months  Ta Period 3  are providers who psaggregated by cat Period N/A  munity based malatironment: Coordinatic the volunteers trained   | Value 238,481  orted stoc  arget  Value  N: D: P: 80 %  rovide ant tegories of arget  Value  aria contro ation and ped and sup | Re Period 3 k outs of n Re Period 3 i-malaria tr f providers Re Period N/A ol activities partnership | sult  Value  131,145  ationality  sult  Value  N:     D:     P: 95 %  reatment a)  sult  Value  Not     Found  do developr | recomm         | nended 30% | antimal 60% | arial contains a second | 100%        | 55% slasting more 119% tment |
| No Level Indicator 2.7 - Poguidelines amor No Level Objective 4 SDA  | ercentage of health fainy time during the pair ercentage of healthcang those surveyed (di         | Period 3  acilities with no repust 3 months  Ta Period 3  are providers who psaggregated by cat Period N/A  munity based malatironment: Coordinatic the volunteers trained   | Value 238,481  orted stoc  rget  Value  N: D: P: 80 %  rrovide antegories of arget  Value  Value                               | Re Period 3 k outs of n Re Period 3 i-malaria tr f providers Re Period N/A ol activities partnership | sult  Value  131,145  ationality  sult  Value  N: D: P: 95 %  reatment a)  sult  Value  Not Found  co developr  malaria pr | recomm         | nended 30% | antimal 60% | arial contains an alaria   | 100%        | 55% slasting more 119% tment |

#### MYN-S10-G07-M

| Objective 5  | Strengthen technical and   | administ             | traative ma | nagement | capacity f | or mala | ria con | trol at a | II levels |  |  |  |  |
|--|--|----------------------|-------------|----------|------------|---------|---------|-----------|-----------|--|--|--|--|
| SDA  | HSS: Human resources   | ISS: Human resources |             |          |            |         |         |           |           |  |  |  |  |
| Indicator 5.1 - Number of health staff trained/retrained |  |                      |             |          |            |         |         |           |           |  |  |  |  |
|  |  | Та                   | rget        | Re       | sult       |         |         |           | 100%      |  |  |  |  |
|  | Period Value Period Value & 50 00 00 000 000 000 000 000 000 000 |                      |             |          |            |         |         |           |           |  |  |  |  |
| No Level 3 4,084 3 1,944 48%                             |  |                      |             |          |            |         |         |           |           |  |  |  |  |

#### MYN-S10-G07-M

Last Updated on: 24 February 2012

| າາ   | Einon | oial | Dorf. | ormar    | -   |
|------|-------|------|-------|----------|-----|
| Z.J. | rman  | Clai |       | 91111611 | ICE |

| 2.3.1. Grant Financial Key Performance Indicators (KPIs) |           |                              |               |  |  |  |  |
|--|-----------|------------------------------|---------------|--|--|--|--|
| Grant Duration (months)                                  | 24 months | Grant Amount                 | 19,262,714 \$ |  |  |  |  |
| % Time Elapsed (as of end date of the latest PU)         | 38%       | % disbursed by TGF (to date) | 88%           |  |  |  |  |
| Time Remaining (as of end date of the latest PU)         | 15 months | Disbursed by TGF (to date)   | 17,014,111 \$ |  |  |  |  |
| Expenditures Rate (as of end date of the latest PU)      | 50%       | Funds Remaining (to date)    | 2,248,603 \$  |  |  |  |  |

| 2.3.2. Program Budget      |                    |                    |                    |                    |                    |                    |                    |                    |
|----------------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|
|                            | Budget<br>Period 1 | Budget<br>Period 2 | Budget<br>Period 3 | Budget<br>Period 4 | Budget<br>Period 5 | Budget<br>Period 6 | Budget<br>Period 7 | Budget<br>Period 8 |
| Period Covered From:       | 01.Jan.11          | 01.Apr.11          | 01.Jul.11          | 01.Oct.11          | 01.Jan.12          | 01.Apr.12          | 01.Jul.12          | 01.Oct.12          |
| Period Covered To:         | 31.Mar.11          | 30.Jun.11          | 30.Sep.11          | 31.Dec.11          | 31.Mar.12          | 30.Jun.12          | 30.Sep.12          | 31.Dec.12          |
| Currency:                  | USD                |
| Cumulative Budget Through: | 6,806,156          | 7,773,024          | 8,883,525          | 9,817,502          | 17,317,698         | 18,642,993         | 20,424,113         | 21,403,015         |
| Summary Period Budget:     | 6,806,156          | 966,868            | 1,110,501          | 933,977            | 7,500,196          | 1,325,295          | 1,781,120          | 978,902            |

#### **Expenditure Categories**

#### **Program Activities**


#### **Implementing Entities**

#### - Comments and additional information

| 2.3.3. Program Expenditures                                |                        |                      |                            |              |                        |  |  |
|--|------------------------|----------------------|----------------------------|--------------|------------------------|--|--|
| Period PU3: 01.Jul.11 - 30.Sep.11                          | Actual Cash<br>Outflow | Cumulative<br>Budget | Cumulative<br>Cash Outflow | Variance     | Reason for variance    |  |  |
| 1. Total cash outflow vs. budget                           | \$ 2,908,179           | \$ 8,883,525         | \$ 4,455,123               | \$ 4,428,402 | Slow burn rate.        |  |  |
| 1a. PR's Total expenditure                                 | \$ 2,171,375           |                      | \$ 3,206,014               |              |                        |  |  |
| 1b. Disbursements to sub-recipients                        | \$ 736,804             |                      | \$ 1,249,109               |              |                        |  |  |
| 1c. Expenditure Adjustments                                |                        |                      |                            |              | Reason for adjustments |  |  |
| 2. Pharmaceuticals & Health Product expenditures vs budget | \$ 1,962,987           |                      | \$ 1,962,987               |              |                        |  |  |
| 2a. Medicines & pharmaceutical products                    | \$ 86,068              |                      | \$ 86,068                  |              |                        |  |  |
| 2b. Health products and health equipment                   | \$ 1,876,919           |                      | \$ 1,876,919               |              |                        |  |  |

#### 2.3.4. Cumulative Program Budget, Expenditures and Disbursement to Date

#### MYN-S10-G07-M



#### MYN-S10-G07-M

Last Updated on: 24 February 2012

#### 2.4. Progress Update and Disbursement Information

| Rating | Description                           |
|--------|---------------------------------------|
| A1     | Exceeding expectations                |
| A2     | Meeting expectations                  |
| B1     | Adequate                              |
| B2     | Inadequate but potential demonstrated |
| С      | Unacceptable                          |

|  | C Unacceptable           |             |         |  |   |                          |              |                        |                      |  |
|--|--------------------------|-------------|---------|--|---|--------------------------|--------------|------------------------|----------------------|--|
| Progress Updates   |                          |             |         |  | Disbursement Information  |                          |              |                        |                      |  |
| PU   | PU Period                |             |         | TGF<br>Rating  | DR  | DR Period<br>Covered     | PR Request   | Disbursement<br>Amount | Disbursement<br>Date |  |
| 0  |                          |             |         | N/A  | 1   | 01.Jan.11 -<br>30.Jun.11 | 7,773,024    | \$ 7,353,080           | 13 Dec 2010          |  |
| Summary of Progress  |                          |             |         |  | Reasons for variance between PR Request and Actual Disbursement |                          |              |                        |                      |  |
|  |                          |             |         | The variance between the PR requested amount and the final disbursement amount is due to the fact that training budgets and one quarter of SR funds were removed as one condition precedent to disbursement of funds for Sub Recipients was still in progress at the time of disbursement. |   |                          |              |                        |                      |  |
|  | F                        | Progress Up | dates   |  |   |                          | Disbursement | Information            |                      |  |
| PU   | PU Period                |             |         | TGF<br>Rating  | DR  | DR Period<br>Covered     | PR Request   | Disbursement<br>Amount | Disbursement<br>Date |  |
| 1  | 01.Jan.11 -<br>31.Mar.11 |             |         | B2   | 1.1   | 01.Jan.11 -<br>31.Mar.11 |              | \$ 289,161             | 20 Dec 2010          |  |
|  | Su                       | mmary of P  | rogress |  | Reasons for variance between PR Request and Actual Disbursement |                          |              |                        |                      |  |
| PR has delayed program implementation.  Consequently, many of the ouput indicators (six out of eleven) are unreported in the reporting period.   |                          |             |         | includes training budget   |   |                          |              |                        |                      |  |
|  | F                        | Progress Up | dates   |  | Disbursement Information  |                          |              |                        |                      |  |
| PU   | PU Period                |             |         | TGF<br>Rating  | DR  | DR Period<br>Covered     | PR Request   | Disbursement<br>Amount | Disbursement<br>Date |  |
| 2  | 01.Apr.11 -<br>30.Jun.11 |             |         | A1   |   |                          |              |                        | N/A                  |  |
| Summary of Progress  |                          |             |         | Reasons for variance between PR Request and Actual Disbursement  |   |                          |              |                        |                      |  |
|  |                          |             |         |  |   |                          |              |                        |                      |  |
|  | F                        | Progress Up | dates   |  | Disbursement Information  |                          |              |                        |                      |  |
| PU   | PU Period                |             |         | TGF<br>Rating  | DR  | DR Period<br>Covered     | PR Request   | Disbursement<br>Amount | Disbursement<br>Date |  |
| 3  | 01.Jul.11 -<br>30.Sep.11 |             |         |  | 2   | 01.Oct.11 -<br>29.Mar.12 | 10,147,446   | \$ 9,371,870           | 15 Feb 2012          |  |
| Summary of Progress  |                          |             |         | Reasons for variance between PR Request and Actual Disbursement  |   |                          |              |                        |                      |  |
| This is the third progress update under the UNOPS grants in Myanmar. The programmatic performance of the malaria program has improved during the reporting period. In general, there is an increasing trend in all programmatic indicators. Comparing current and previous progress updates, the final quantitative rating increased from C to B1 with an average performance of the Top Ten indicators (including training) increased from 28% to 61%, and average performance of all indicators increased from 27% to 68%. Four Top ten indicators are still rated either C or B2 during this reporting period. The PR has confirmed that substantial progress has been made to ensure that the achievement under these indicators is improved during the next reporting period. |                          |             |         |  |   |                          |              |                        |                      |  |

### 2.5. Contextual Information

Explanatory Notes

### MYN-S10-G07-M

Title

| 2.6. Phase 2/ Periodic Review Grant Renewal                  |  |                         |           |  |  |  |  |
|--|--|-------------------------|-----------|--|--|--|--|
| Performance Rating   |  | Recommendation Category |           |  |  |  |  |
| Rationale for Phase 2/ Periodic R                            | Rationale for Phase 2/ Periodic Review Recommendation Category |                         |           |  |  |  |  |
|  |  |                         |           |  |  |  |  |
| Rationale for Phase 2/ Periodic Review Recommendation Amount |  |                         |           |  |  |  |  |
|  |  |                         |           |  |  |  |  |
| Time-bound Actions   |  |                         |           |  |  |  |  |
| Iss  | sues   | De                      | scription |  |  |  |  |

MYN-S10-G07-M